UCB Ventures makes its first direct investment
Brussels, Belgium, 13 June 2018. — Today, UCB Ventures announces its first direct investment in the oversubscribed $15.7 million Series A Financing Round for StrideBio, Inc., a US-based biotechnology company developing novel adeno-associated viral (AAV) vectors for in vivo gene therapies of rare diseases. The financing was led by Hatteras Venture Partners, and in addition to UCB Ventures, co-investors include Takeda Ventures, Inc. and Alexandria Venture Investments, LLC. Erica Whittaker, PhD, Vice President, Head of UCB Ventures, and Jayson Punwani, PhD, Partner, Takeda Ventures, Inc. have joined StrideBio’s Board of Directors.read more
About UCB Ventures
- UCB Ventures is an evergreen strategic corporate venture fund established in 2017. Our mandate is to explore value creation and learning from innovative, longer term and higher risk opportunities beyond the current focus areas of our parent company, Belgium-based UCB Pharma.
- A proportion of the €150 million UCB Ventures fund has already been committed as fund-to-fund investments in selected healthcare venture capital funds.
- The remaining capital is being deployed as direct equity investments into early stage opportunities, assets or platforms, that address unmet patient needs in neurology, immunology and muscular skeletal/bone health.